Literature DB >> 24315208

Lung clearance index: evidence for use in clinical trials in cystic fibrosis.

L Kent1, P Reix2, J A Innes3, S Zielen4, M Le Bourgeois5, C Braggion6, S Lever7, H G M Arets8, K Brownlee9, J M Bradley1, K Bayfield10, K O'Neill11, D Savi12, D Bilton13, A Lindblad14, J C Davies15, I Sermet16, K De Boeck17.   

Abstract

The ECFS-CTN Standardisation Committee has undertaken this review of lung clearance index as part of the group's work on evaluation of clinical endpoints with regard to their use in multicentre clinical trials in CF. The aims were 1) to review the literature on reliability, validity and responsiveness of LCI in patients with CF, 2) to gain consensus of the group on feasibility of LCI and 3) to gain consensus on answers to key questions regarding the promotion of LCI to surrogate endpoint status. It was concluded that LCI has an attractive feasibility and clinimetric properties profile and is particularly indicated for multicentre trials in young children with CF and patients with early or mild CF lung disease. This is the first article to collate the literature in this manner and support the use of LCI in clinical trials in CF.
© 2013. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. All rights reserved.

Entities:  

Keywords:  Clinimetric properties; Lung clearance index; Multiple breath washout; Outcome measures; Surrogate endpoints

Mesh:

Substances:

Year:  2013        PMID: 24315208     DOI: 10.1016/j.jcf.2013.09.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  42 in total

1.  A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial.

Authors:  Eric W F W Alton; A Christopher Boyd; David J Porteous; Gwyneth Davies; Jane C Davies; Uta Griesenbach; Tracy E Higgins; Deborah R Gill; Stephen C Hyde; J Alastair Innes
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

2.  Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.

Authors:  Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

Review 3.  Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis.

Authors:  Pi Chun Cheng; Stamatia Alexiou; Ronald C Rubenstein
Journal:  Expert Rev Respir Med       Date:  2019-04-08       Impact factor: 3.772

4.  Lung Clearance Index (LCI) in Patients with Bronchiolitis Obliterans: A Preliminary Report and Comparison to Cystic Fibrosis Patients.

Authors:  Michal Gur; Karin Yaacoby-Bianu; Anat Ilivitzki; Ronen Bar-Yoseph; Vered Nir; Fahed Hakim; Yazeed Toukan; Lea Bentur
Journal:  Lung       Date:  2016-08-31       Impact factor: 2.584

5.  Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.

Authors:  Padmaja Subbarao; Carlos Milla; Paul Aurora; Jane C Davies; Stephanie D Davis; Graham L Hall; Sonya Heltshe; Philipp Latzin; Anders Lindblad; Jessica E Pittman; Paul D Robinson; Margaret Rosenfeld; Florian Singer; Tim D Starner; Felix Ratjen; Wayne Morgan
Journal:  Ann Am Thorac Soc       Date:  2015-06

6.  Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.

Authors:  Carlos E Milla; Felix Ratjen; Gautham Marigowda; Fang Liu; David Waltz; Margaret Rosenfeld
Journal:  Am J Respir Crit Care Med       Date:  2017-04-01       Impact factor: 21.405

7.  Using Hyperpolarized 129Xe MRI to Quantify the Pulmonary Ventilation Distribution.

Authors:  Mu He; Bastiaan Driehuys; Loretta G Que; Yuh-Chin T Huang
Journal:  Acad Radiol       Date:  2016-09-09       Impact factor: 3.173

8.  Potential for noninvasive assessment of lung inhomogeneity using highly precise, highly time-resolved measurements of gas exchange.

Authors:  James E Mountain; Peter Santer; David P O'Neill; Nicholas M J Smith; Luca Ciaffoni; John H Couper; Grant A D Ritchie; Gus Hancock; Jonathan P Whiteley; Peter A Robbins
Journal:  J Appl Physiol (1985)       Date:  2017-10-26

9.  Impact of Software Settings on Multiple-Breath Washout Outcomes.

Authors:  Selina Summermatter; Florian Singer; Philipp Latzin; Sophie Yammine
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

Review 10.  Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell.

Authors:  Barbara Bosch; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2015-11-14       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.